Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.

Literature DB >> 8429309

Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.

Abstract

The efficacy of two routes of apomorphine, subcutaneous (SC) and sublingual (SL), successively administered in 7 Parkinsonian patients with motor fluctuations, was compared in reducing the daily duration of "off" phases. The mean duration of SC and SL treatment was 7.7 and 6.8 months respectively. The mean time spent in "off" phase was 55% after SC and 68% after SL treatment. The mean time before turning "on" after an "off" period was 14 minutes after SC and 28 minutes after SL treatment. Two patients developed stomatitis after SL route. SL apomorphine may be helpful in the treatment of motor fluctuations in PD.

Entities: Chemical Disease Species

Mesh：

Substances：
Apomorphine

Year: 1993 PMID： 8429309 PMCID： PMC1014775 DOI： 10.1136/jnnp.56.1.101

Source DB: PubMed Journal: J Neurol Neurosurg Psychiatry ISSN： 0022-3050 Impact factor: 10.154

8 in total

1. Intranasal apomorphine in Parkinson's disease.

Authors: B Kleedorfer; N Turjanski; R Ryan; A J Lees; C Milroy; G M Stern
Journal: Neurology Date: 1991-05 Impact factor: 9.910

2. Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study.

Authors: J L Montastruc; O Rascol; J M Senard; V Gualano; H Bagheri; G Houin; A Lees; A Rascol
Journal: Clin Neuropharmacol Date: 1991-10 Impact factor: 1.592

3. Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations.

Authors: A J Hughes; R Webster; M Bovingdon; A J Lees; G M Stern
Journal: Clin Neuropharmacol Date: 1991-12 Impact factor: 1.592

4. Sublingual apomorphine and Parkinson's disease.

Authors: A J Lees; J L Montastruc; N Turjanski; O Rascol; B Kleedorfer; H Peyro Saint-Paul; G M Stern; A Rascol
Journal: J Neurol Neurosurg Psychiatry Date: 1989-12 Impact factor: 10.154

5. Subcutaneous apomorphine in the treatment of Parkinson's disease.

Authors: J P Frankel; A J Lees; P A Kempster; G M Stern
Journal: J Neurol Neurosurg Psychiatry Date: 1990-02 Impact factor: 10.154

6. Subcutaneous apomorphine in parkinsonian on-off oscillations.

Authors: C M Stibe; A J Lees; P A Kempster; G M Stern
Journal: Lancet Date: 1988-02-20 Impact factor: 79.321

7. Subcutaneous apomorphine in Parkinson's disease.

Authors: W Poewe; B Kleedorfer; F Gerstenbrand; W Oertel
Journal: Lancet Date: 1988-04-23 Impact factor: 79.321

8. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].

Authors: P Pollak; A S Champay; J M Gaio; M Hommel; A L Benabid; J Perret
Journal: Rev Neurol (Paris) Date: 1990 Impact factor: 2.607

8 in total

6 in total

Review 1. Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

Authors: L Dépatie; S Lal
Journal: J Psychiatry Neurosci Date: 2001-05 Impact factor: 6.186

Review 2. Old Drugs, New Delivery Systems in Parkinson's Disease.

Authors: Harsh V Gupta; Kelly E Lyons; Rajesh Pahwa
Journal: Drugs Aging Date: 2019-09 Impact factor: 3.923

3. Regulation of aromatic L-amino acid decarboxylase in rat striatal synaptosomes: effects of dopamine receptor agonists and antagonists.

Authors: M Y Zhu; A V Juorio; I A Paterson; A A Boulton
Journal: Br J Pharmacol Date: 1994-05 Impact factor: 8.739